Pfizer Inc. (PFE) Position Trimmed by Biegel & Waller LLC

Biegel & Waller LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 35.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,020 shares of the biopharmaceutical company’s stock after selling 2,798 shares during the quarter. Biegel & Waller LLC’s holdings in Pfizer were worth $219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. OppenheimerFunds Inc. grew its holdings in shares of Pfizer by 32.2% in the third quarter. OppenheimerFunds Inc. now owns 6,890,372 shares of the biopharmaceutical company’s stock worth $303,659,000 after purchasing an additional 1,678,438 shares during the last quarter. Viridian Ria LLC grew its holdings in shares of Pfizer by 0.9% in the fourth quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 280 shares during the last quarter. Prio Wealth Limited Partnership grew its holdings in shares of Pfizer by 3.2% in the third quarter. Prio Wealth Limited Partnership now owns 1,039,655 shares of the biopharmaceutical company’s stock worth $45,817,000 after purchasing an additional 32,071 shares during the last quarter. Rehmann Capital Advisory Group grew its holdings in shares of Pfizer by 1.4% in the third quarter. Rehmann Capital Advisory Group now owns 125,426 shares of the biopharmaceutical company’s stock worth $5,528,000 after purchasing an additional 1,759 shares during the last quarter. Finally, Focused Wealth Management Inc grew its holdings in shares of Pfizer by 160.7% in the third quarter. Focused Wealth Management Inc now owns 83,780 shares of the biopharmaceutical company’s stock worth $3,692,000 after purchasing an additional 51,644 shares during the last quarter. 69.17% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Rady A. Johnson sold 8,700 shares of Pfizer stock in a transaction on Friday, March 15th. The shares were sold at an average price of $41.13, for a total value of $357,831.00. Following the sale, the insider now owns 59,797 shares in the company, valued at $2,459,450.61. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Dawn Rogers sold 15,002 shares of Pfizer stock in a transaction on Monday, March 4th. The shares were sold at an average price of $42.98, for a total transaction of $644,785.96. Following the completion of the sale, the executive vice president now owns 28,722 shares in the company, valued at approximately $1,234,471.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 288,726 shares of company stock worth $12,534,617. 0.09% of the stock is currently owned by company insiders.

PFE has been the topic of several recent analyst reports. UBS Group cut shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Wednesday, January 23rd. ValuEngine cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Zacks Investment Research cut shares of Pfizer from a “hold” rating to a “sell” rating in a report on Friday, January 25th. Credit Suisse Group restated a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, January 28th. Finally, Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Thursday, January 31st. Fourteen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $45.83.

NYSE:PFE opened at $41.47 on Friday. The firm has a market capitalization of $246.87 billion, a P/E ratio of 13.82, a P/E/G ratio of 2.38 and a beta of 0.71. Pfizer Inc. has a twelve month low of $35.32 and a twelve month high of $46.47. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.10. The business had revenue of $13.12 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.77 earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be issued a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.47%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Position Trimmed by Biegel & Waller LLC” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/18/pfizer-inc-pfe-position-trimmed-by-biegel-waller-llc.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Why is the price-sales ratio important?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.